ACS chemical neuroscience molecule spotlight on begacestat (GSI-953)

Research output: Contribution to journalReview article

23 Citations (Scopus)

Abstract

A "second generation" γ-secretase, Begacestat (GSI-953), which is more selective against Notch-signaling, has shown promise in recent Phase I clinical trials. Begacestat, a novel, 2,5-disubsitituted thiophene sulfonamide from Wyeth (now Pfizer) is under evaluation for the treatment of Alzheimer's disease.

Original languageEnglish (US)
Pages (from-to)3-4
Number of pages2
JournalACS Chemical Neuroscience
Volume3
Issue number1
DOIs
StatePublished - Jan 18 2012

Fingerprint

Neurosciences
Thiophenes
Amyloid Precursor Protein Secretases
Clinical Trials, Phase I
Molecules
Sulfonamides
Alzheimer Disease
begacestat

Keywords

  • Alzheimer's disease
  • Aβ-peptides
  • GSI
  • γ-secretase inhibitors

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Cognitive Neuroscience
  • Cell Biology

Cite this

ACS chemical neuroscience molecule spotlight on begacestat (GSI-953). / Hopkins, Corey R.

In: ACS Chemical Neuroscience, Vol. 3, No. 1, 18.01.2012, p. 3-4.

Research output: Contribution to journalReview article

@article{144d263936d040db8c2d0421cfba1270,
title = "ACS chemical neuroscience molecule spotlight on begacestat (GSI-953)",
abstract = "A {"}second generation{"} γ-secretase, Begacestat (GSI-953), which is more selective against Notch-signaling, has shown promise in recent Phase I clinical trials. Begacestat, a novel, 2,5-disubsitituted thiophene sulfonamide from Wyeth (now Pfizer) is under evaluation for the treatment of Alzheimer's disease.",
keywords = "Alzheimer's disease, Aβ-peptides, GSI, γ-secretase inhibitors",
author = "Hopkins, {Corey R.}",
year = "2012",
month = "1",
day = "18",
doi = "10.1021/cn200124u",
language = "English (US)",
volume = "3",
pages = "3--4",
journal = "ACS Chemical Neuroscience",
issn = "1948-7193",
publisher = "American Chemical Society",
number = "1",

}

TY - JOUR

T1 - ACS chemical neuroscience molecule spotlight on begacestat (GSI-953)

AU - Hopkins, Corey R.

PY - 2012/1/18

Y1 - 2012/1/18

N2 - A "second generation" γ-secretase, Begacestat (GSI-953), which is more selective against Notch-signaling, has shown promise in recent Phase I clinical trials. Begacestat, a novel, 2,5-disubsitituted thiophene sulfonamide from Wyeth (now Pfizer) is under evaluation for the treatment of Alzheimer's disease.

AB - A "second generation" γ-secretase, Begacestat (GSI-953), which is more selective against Notch-signaling, has shown promise in recent Phase I clinical trials. Begacestat, a novel, 2,5-disubsitituted thiophene sulfonamide from Wyeth (now Pfizer) is under evaluation for the treatment of Alzheimer's disease.

KW - Alzheimer's disease

KW - Aβ-peptides

KW - GSI

KW - γ-secretase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84856045551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856045551&partnerID=8YFLogxK

U2 - 10.1021/cn200124u

DO - 10.1021/cn200124u

M3 - Review article

C2 - 22860177

AN - SCOPUS:84856045551

VL - 3

SP - 3

EP - 4

JO - ACS Chemical Neuroscience

JF - ACS Chemical Neuroscience

SN - 1948-7193

IS - 1

ER -